Viking Therapeutics Inc. (VKTX)
VKTX trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1607678/000119312526046876/0001193125-26-046876-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | VKTX on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2015 |
| SEC CIK | 0001607678 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $0 |
| Net income | -$359.6M |
| Operating income | -$393.3M |
| Net margin | Needs revenue and net income |
| Operating margin | Operating income not reported |
| Revenue growth | No prior-year revenue to compare |
| Cash | $165.8M |
| Total assets | $715.7M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | Needs market cap and revenue |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-10-29 |
| Cash and burn | $677.6M cash; operating cash flow -$115.7M a quarter. | Report 2026-09-30 |
| Shares outstanding | 127,522,189 (2026-10-15); 113,036,344 a year earlier; 100,028,953 three years earlier. | Cover page 2026-10-15 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 1 S-3/F-3 shelf filings; 4 424B5 takedowns, 4 at the market | Latest 2026-09-25 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | CBIZ CPAs P.C., Costa Mesa, California, United States; changed auditors 1 time in 24 months | 8-K 4.01 2025-04-23 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $150K, sold $22.0M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $0 | -$183.2M | -$138.2M | $677.6M | No debt tags | $0 | 10-Q 2026-10-29 |
| Q2 2026 2026-06-30 | $0 | -$128.0M | -$125.2M | $125.8M | No debt tags | $0 | 10-Q 2026-07-29 |
| Q1 2026 2026-03-31 | $0 | -$158.3M | -$114.0M | $118.1M | No debt tags | $0 | 10-Q 2026-04-30 |
| Q4 2025 2025-12-31 | $0 | -$157.7M | -$85.3M | $165.8M | No debt tags | $0 | 10-K 2026-02-11 |
| Q3 2025 2025-09-30 | $0 | -$90.8M | -$94.0M | $100.4M | No debt tags | $0 | 10-Q 2026-10-29 |
| Q2 2025 2025-06-30 | $0 | -$65.6M | -$47.1M | $33.9M | No debt tags | $0 | 10-Q 2026-07-29 |
| Q1 2025 2025-03-31 | $0 | -$45.6M | -$52.3M | $37.9M | No debt tags | $0 | 10-Q 2026-04-30 |
| Q4 2024 2024-12-31 | $0 | -$35.4M | -$31.2M | $26.7M | No debt tags | $0 | 10-K 2026-02-11 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2026-09-25 |
| Latest annual report | 10-K | 2026-02-11 |
| Latest quarterly / interim | 10-Q | 2026-10-29 |
| Latest current report | 8-K | 2026-10-28 |
| Latest proxy | DEFA14A | 2026-04-01 |
Source: SEC EDGAR submissions feed, 652 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +8.9% |
| 1 month | +9.6% |
| 3 months | -11.3% |
| Year to date | -16.9% |
| 1 year | -25.1% |
| From 52-week high | -30.6% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| ARQT | Arcutis Biotherapeutics Inc. | $27.15 | -3.93% | $3.4B |
| VRDN | Viridian Therapeutics Inc. | $29.80 | -3.47% | $3.4B |
| IRON | Disc Medicine Inc. | $76.59 | -4.26% | $3.5B |
| ELVN | Enliven Therapeutics Inc. | $47.62 | -2.42% | $3.5B |
| PBLS | Parabilis Medicines Inc. | $28.45 | +0.07% | $3.5B |
| AMLX | Amylyx Pharmaceuticals Inc. | $27.80 | -8.22% | $3.6B |
| ACAD | ACADIA Pharmaceuticals Inc. | $18.67 | -0.43% | $3.2B |
| ABCL | AbCellera Biologics Inc. Common Shares | $11.12 | -3.22% | $3.6B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier